# USE OF PSYCHOTROPIC DRUGS IN CHILDREN AND ADOLESCENTS IN CATALONIA. A cohort study with real world data from the electronic primary health care record from 2007-2017. (PEPSICAT)

First published: 22/02/2019
Last updated: 14/03/2024





# Administrative details

| EU PAS number    |  |
|------------------|--|
| EUPAS28375       |  |
| Study ID         |  |
| 28503            |  |
| DARWIN EU® study |  |
| No               |  |
| Study countries  |  |
| Spain            |  |

#### Study description

This project has four main objectives: to describe in children <18 years the use of psychotropic drugs during the last decade, to describe their psychiatric diagnoses, to describe the baseline characteristics when starting treatment with psychotropic drugs and, to describe the consumption pattern of psychotropic drugs. As secondary objectives: to analyse factors associated with the use of different psychotropic drugs and factors related to the diagnosis of mental illness in patients under treatment with psychotropic drugs and to describe the adherence to psychotropic treatment. As exploratory objectives, an attempt will be made to correlate the maternal obstetric and psychiatric history with the consumption of psychotropic medication in the offspring and to analyse the reasons for the lack of a diagnostic record of mental pathology in patients with psychotropic treatment. Methods: Descriptive observational study will from 2007-2017 in the population under the age of 18 with at least one prescription for a psychotropic drug. Two studies will be carried out: one to estimate the prevalence of psychotropic drug use and psychiatric pathology diagnoses and the second one to estimate the incidence of psychotropic drug use in the <18 year population. This population will be followed until the end of the study or the impossibility to obtain information (death/transfer). The treatment period with this first psychotropic drug and the addition of other psychotropic drugs or the change of psychotropic treatment will be analysed during the follow-up. Data source: SIDIAP (Sistema de Información para el Desarrollo de la Investigación en Atención Primaria) database, which contains anonymized clinical information on approximately 80% of the population of Catalonia (Spain). Information will be completed with data from the Basic Minimum Data Set for outpatient mental health care (CMBD-SMA). Data will be stratified by sex and age groups.

#### **Study status**

Ongoing

# Research institutions and networks

#### Institutions



# Contact details

# Study institution contact

Ainhoa Gome-Lumbreras agomez@idiapjgol.info

Study contact

agomez@idiapjgol.info

#### **Primary lead investigator**

Gomez-Lumbreras Ainhoa

Primary lead investigator

# Study timelines

#### Date when funding contract was signed

Planned: 16/02/2018

#### Study start date

Planned: 01/06/2018 Actual: 01/06/2018

#### Data analysis start date

Planned: 14/06/2018

# Date of interim report, if expected

Planned: 05/10/2018 Actual: 05/10/2018

#### **Date of final study report**

Planned: 31/12/2020

# Sources of funding

Other

# More details on funding

Catalan Health Department

# Study protocol

PEPSICAT\_ENCePP.pdf (283.36 KB)

# Regulatory

Is the study required by a Risk Management Plan (RMP)?

Not applicable

# Other study registration identification numbers and links

Catalan Health Department

SLT006/17/00309 https://web.gencat.cat/web/shared/OVT/Departaments/SLT/Documents/Notational contents of the property of the

classification: EPA-OD. UMO 2007-17. Code: IUI-FLU-2018-01

# Methodological aspects

Study type

Study type list

**Study type:** 

Non-interventional study

Scope of the study:

Drug utilisation

Main study objective:

To describe the use of psychotropic drugs in children <18 years from Catalonia during 2007-2017. To describe the psychiatric diagnoses in the <18 years population consuming psychotropic drugs. To describe the consumption pattern and characteristics of patients <18 years who start treatment with psychotropic drugs.

# Study Design

#### Non-interventional study design

Cohort

# Study drug and medical condition

#### **Anatomical Therapeutic Chemical (ATC) code**

(N06BA) Centrally acting sympathomimetics

Centrally acting sympathomimetics

(N06A) ANTIDEPRESSANTS

**ANTIDEPRESSANTS** 

(N05A) ANTIPSYCHOTICS

**ANTIPSYCHOTICS** 

(N05B) ANXIOLYTICS

**ANXIOLYTICS** 

(N05C) HYPNOTICS AND SEDATIVES

HYPNOTICS AND SEDATIVES

#### Medical condition to be studied

Psychiatric investigation

# Population studied

#### Age groups

- Term newborn infants (0 27 days)
- Infants and toddlers (28 days 23 months)
- Children (2 to < 12 years)
- Adolescents (12 to < 18 years)</li>

#### **Estimated number of subjects**

300000

# Study design details

#### Data analysis plan

All data management, purification, descriptive calculation and statistical analysis processes will be carried out using the statistical package R 3.3(2016)Demographic data and baseline characteristics of the population will be described by relative and absolute frequencies for the categorical variables and median standard deviation or median and interquartile range for the continuous variables. In the bivariate analysis, Chi-square test or the exact Fischer test for the categorical variables and the t-test of Student or the U-test of Mann-Whitney for the continuous variables according to their distributionEvaluation of psychotropic consumption based on psychiatric/obstetric maternal records, as well as the risk related to the persistence/adherence of these in patients with an age range of 16 to 18 years old, will be performed using multiple logistic regression models or proportional risk models (Cox).Adjustment for risk factors based on the characteristics of the study population

# Data management

#### **FNCePP Seal**

The use of the ENCePP Seal has been discontinued since February 2025.

The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

#### Data sources

#### Data source(s)

The Information System for Research in Primary Care (SIDIAP)

#### Data source(s), other

**SIDIAP** 

#### Data sources (types)

Administrative healthcare records (e.g., claims)

Drug dispensing/prescription data

Electronic healthcare records (EHR)

# Use of a Common Data Model (CDM)

#### **CDM** mapping

No

# Data quality specifications

#### **Check conformance**

Unknown

# **Check completeness**

Unknown

# **Check stability**

Unknown

# **Check logical consistency**

Unknown

# Data characterisation

#### **Data characterisation conducted**

No